相关实验视频

Updated: Jul 4, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

作为心脏纤维化治疗点的短链-CoA脱酶

Zhaohui Shu^1,2, Jingyun Feng^1,2, Lanting Liu^1,2

¹School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China ; and.

Journal of cardiovascular pharmacology

|February 7, 2024

概括

短链乙-CoA脱酶 (SCAD) 保护心脏纤维化. 降低高血压中的SCAD水平会使纤维化恶化,这表明SCAD是治疗心脏病的治疗点.

科学领域:

心血管生物学心血管生物学
分子心脏病学分子心脏病学
纤维化研究纤维化研究

背景情况:

心脏纤维化,细胞外基质的不平衡,有助于心力衰竭.
众所周知,短链乙-CoA脱酶 (SCAD) 能够抑制病理性心脏缩.

研究的目的:

调查SCAD在心脏纤维化发展中的作用.
探索SCAD作为心脏纤维化的潜在治疗点.

主要方法:

在体内研究使用自发高血压大鼠 (SHR) 和SCAD淘汰赛小鼠.
用心脏纤维细胞 (CFs) 进行的体外实验涉及血管素II (Ang II),SCAD siRNA和腺病毒-SCAD.
对高血压患者心脏组织中SCAD表达的分析.

主要成果:

在SHR心脏和Ang II治疗的CF患者中,SCAD表达减少.
游泳训练增加了SCAD,并减少了SHR中的纤维化.
在CF和SHR模型中的SCAD操纵表明其抗纤维作用,减少增殖,α-SMA和原.
SCAD缺乏症加剧了心脏纤维化.

结论:

SCAD对心脏纤维化有负面调节作用.
SCAD代表了缓解心脏纤维化和相关心脏病的潜在治疗标.

更多相关视频

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...